Cargando…
What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
BACKGROUND: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills (‘polypills’) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical tria...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211054/ https://www.ncbi.nlm.nih.gov/pubmed/22080542 http://dx.doi.org/10.1136/bmjopen-2011-000372 |
_version_ | 1782215797945401344 |
---|---|
author | Jan, Stephen Usherwood, Tim Brien, Jo Anne Peiris, David Rose, John Hayman, Noel Howard, Kirsten Redfern, Julie Laba, Tracey Cass, Alan Patel, Anushka |
author_facet | Jan, Stephen Usherwood, Tim Brien, Jo Anne Peiris, David Rose, John Hayman, Noel Howard, Kirsten Redfern, Julie Laba, Tracey Cass, Alan Patel, Anushka |
author_sort | Jan, Stephen |
collection | PubMed |
description | BACKGROUND: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills (‘polypills’) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy. METHODS/DESIGN: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour. ETHICS AND DISSEMINATION: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations. |
format | Online Article Text |
id | pubmed-3211054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32110542011-12-01 What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study Jan, Stephen Usherwood, Tim Brien, Jo Anne Peiris, David Rose, John Hayman, Noel Howard, Kirsten Redfern, Julie Laba, Tracey Cass, Alan Patel, Anushka BMJ Open Health Services Research BACKGROUND: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills (‘polypills’) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy. METHODS/DESIGN: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour. ETHICS AND DISSEMINATION: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations. BMJ Group 2011-10-27 /pmc/articles/PMC3211054/ /pubmed/22080542 http://dx.doi.org/10.1136/bmjopen-2011-000372 Text en © 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Health Services Research Jan, Stephen Usherwood, Tim Brien, Jo Anne Peiris, David Rose, John Hayman, Noel Howard, Kirsten Redfern, Julie Laba, Tracey Cass, Alan Patel, Anushka What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study |
title | What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study |
title_full | What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study |
title_fullStr | What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study |
title_full_unstemmed | What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study |
title_short | What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study |
title_sort | what determines adherence to treatment in cardiovascular disease prevention? protocol for a mixed methods preference study |
topic | Health Services Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211054/ https://www.ncbi.nlm.nih.gov/pubmed/22080542 http://dx.doi.org/10.1136/bmjopen-2011-000372 |
work_keys_str_mv | AT janstephen whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT usherwoodtim whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT brienjoanne whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT peirisdavid whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT rosejohn whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT haymannoel whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT howardkirsten whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT redfernjulie whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT labatracey whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT cassalan whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy AT patelanushka whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy |